Li M Fu
Overview
Explore the profile of Li M Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
111
Followers
0
Related Specialties
Related Specialties
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Analysis of Parkinson's disease pathophysiology using an integrated genomics-bioinformatics approach
Fu L, Fu K
Pathophysiology
. 2014 Dec;
22(1):15-29.
PMID: 25466606
The pathogenesis and pathophysiology of a disease determine how it should be diagnosed and treated. Yet, understanding the cause and mechanisms of progression often requires intensive human efforts, especially for...
2.
Fu L
Curr Pharm Des
. 2013 Nov;
20(27):4307-18.
PMID: 24245763
Tuberculosis (TB) remains to be a global major public-health threat, causing millions of deaths each year. A major difficulty in dealing with TB is that the causative bacterium, Mycobacterium tuberculosis,...
3.
Fu L, Tai S
Int J Microbiol
. 2009 Dec;
2009:879621.
PMID: 20016672
Tuberculosis is a leading infectious disease causing millions of deaths each year. How to eradicate mycobacterial persistence has become a central research focus for developing next-generation TB drugs. Yet, the...
4.
Fu L, Shinnick T
EURASIP J Bioinform Syst Biol
. 2008 Feb;
:23054.
PMID: 18253472
Sequencing the complete genome of Mycobacterium tuberculosis H37Rv is a major milestone in the genome project and it sheds new light in our fight with tuberculosis. The genome contains around...
5.
Fu L, Fu-Liu C
BMC Microbiol
. 2007 May;
7:37.
PMID: 17501996
Background: Tuberculosis remains a leading infectious disease with global public health threat. Its control and management have been complicated by multi-drug resistance and latent infection, which prompts scientists to find...
6.
Fu L, Shinnick T
Tuberculosis (Edinb)
. 2006 Aug;
87(1):63-70.
PMID: 16890025
The availability of the complete sequence of Mycobacterium tuberculosis genome coupled with microarray technology has enabled a high-throughput approach to the pharmacogenomics of this organism. Isoniazid (INH) is a first-line...
7.
Fu L, Shinnick T
J Infect
. 2006 Jul;
54(3):277-84.
PMID: 16822547
Objective: Multi-drug resistance and latent infection are two major issues in current tuberculosis (TB) control and management. Capreomycin is an important drug used for TB with multi-drug resistance. A recent...
8.
Fu L
Tuberculosis (Edinb)
. 2005 Oct;
86(2):134-43.
PMID: 16246625
DNA microarrays have rapidly emerged as an important tool for Mycobacterium tuberculosis research. While the microarray approach has generated valuable information, a recent survey has found a lack of correlation...
9.
Fu L, Fu-Liu C
BMC Bioinformatics
. 2005 Mar;
6:67.
PMID: 15784140
Background: Microarray devices permit a genome-scale evaluation of gene function. This technology has catalyzed biomedical research and development in recent years. As many important diseases can be traced down to...
10.
Fu L, Fu-Liu C
FEBS Lett
. 2004 Mar;
561(1-3):186-90.
PMID: 15013775
Differential diagnosis among a group of histologically similar cancers poses a challenging problem in clinical medicine. Constructing a classifier based on gene expression signatures comprising multiple discriminatory molecular markers derived...